present the extremely rare case of a patient with DIHS associated with HHV-6 and cytomegalovirus infection induced by sulfasalazine combined with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) caused by interstitial pneumonia (IP).
Case Report
A 67-year-old male patient with a past history of rheumatism (RA), hypertension, and subarachnoid hemorrhage presented to a health facility with right hemiparalysis and aphasia as the chief complaints and was subsequently transferred to our hospital. A diagnosis of left embolic cerebral infarction that occurred during a trial for RA was made. His level consciousness as assessed by the Japan Coma Scale was I-3. Blood pressure was 147/88 mmHg and body temperature was 36.0°C. Left upper limb paralysis and left joint deviation were observed at admission.
Laboratory and radiological investigations were conducted, and the results were as follows. Blood count: white blood cells, 6.1 × 10 3 /μL; red blood cells, 495 × 10 4 /μL; hemoglobin, 15.6 g/dL; hematocrit, 46.7%; platelets, 25.2 × 10 4 /μL; biochemistry: Na, 143 mmol/ L; K, 4.4 mmol/L; Cl, 104 mmol/L; hemoglobin A1C, 6.0%; low-density lipoprotein, 156 mg/dL; C-reactive protein, 0.02 mg/dL; coagulation: D-dimer less than 0.3 μg/mL. The electrocardiography showed a heart rate of 72 beats per min and no abnormal findings. Magnetic resonance imaging of the head at admission ( Figures  1A, B ) showed extensive embolic cerebral infarction in the vessel-dominated region of the left middle cerebral artery.
On day 1, external decompression was done to relieve cerebral herniation caused by the cerebral infarction. On day 2, we began a course of levetiracetam at a dose of 1,000 mg/day to prevent convulsions. Based on the history of RA, on day 7, salazosulfapyridine was administered at a dose of 500 mg/day and increased after 7 days (i.e., on day 14) to 1,000 mg/day. The postoperative computed tomography (CT) following cranioplasty showed no increase in hemorrhagic infarction.
On day 37, dabigatran 300 mg/day was started to prevent the recurrence of cerebral infarction. On day 41, the patient developed fever. The following day (day 42), edema and erythema appeared on his face ( Figure  2A) , and erythema and rash also appeared on his trunk and extremities ( Figure 2B ). Due to the gradual onset of erythroderma, topical application of diphenhydramine and oral administration of fexofenadine hydrochloride at a dose of 120 mg/day was started.
The CT performed on day 43 showed inflammatory findings in the ileocecal area ( Figure 3A ) and a mild nodule shadow at the lower right lung ( Figure 3B ). We suspected that the drug eruption was caused by the dabigatran, and the oral administration of dabigatran was then stopped. On day 45, the patient developed diarrhea and was started on clostridium butyricum at a dose of 6 g/day. On day 50, his respiratory function deteriorated (saturation of percutaneous oxygen, SpO 2 90%) and oxygen was administered. On day 51, a drug lymphocyte stimulation test was performed for levetiracetam and dabigatran. Both results were negative. Due to further deterioration of his respiratory function on day 53 (saturation of percutaneous oxygen, SpO 2 80%), the oral administration of salazosulfapyridine was discontinued. A steroid pulse of methylprednisolone at a dose of 1 g/day for a period of 3 days was administered to prevent exacerbation of the IP ( Figures 4A and 4B ). Following this, the dose of methylprednisolone was reduced to 40 mg/ day. Given the possibility of steroidogenic glucose tolerance abnormality, concurrent insulin therapy was administered in combination with methylprednisolone. Cardiac ultrasound examination performed on day 55 showed a pericardial effusion with normal wall motion. The CT performed on day 59 showed that the IP had worsened and that there was pericardial effusion, while the inflammatory findings in the ileocecal area had decreased ( Figures 5A and 5B ).
Due to malaise caused by hyponatremia on day 60, fluids were restricted on suspicion of SIADH caused by the IP. The hyponatremia was then gradually corrected. The patient then developed stomatitis, and a dexamethasone ointment was prescribed. The fever, erythema, and rash recurred on day 66. A CT performed on day 66 (Figures 6A and 6B) showed that the pericardial effusion was no longer present. The IP worsened and prednisolone was increased to a dose of 60 mg/day on day 67.
On day 72, we suspected that the patient had DIHS that had been induced by salazosulfapyridine, and antibody examinations for HHV-6, HHV-7, Epstein-Barr virus (EBV), and cytomegalovirus were performed. The quantification test for HHV-6 DNA was negative (1.4 × 10 2 copies), and the quantification of HHV-7 DNA was also negative. EB anti-viral capsid antigen (VCA)immunoglobulin G (IgG) was increased 160-fold and EB anti-VCA-IgM was negative. EB anti-EB nuclear antigen was increased 40-fold, which provided evidence of past EBV infection. As there were positive findings of cytomegalovirus-IgG (enzyme immunoassay) at 15.3 and cytomegalovirus-IgM (enzyme immunoassay) at 1.11, cytomegalovirus reactivation was suspected. Two months following the onset of DIHS, the patient was transferred to a rehabilitation center with a modified Rankin Scale score of 3. After transfer, his skin symptoms recurred intermittently, and psychiatric symptoms were also observed. At 10 months following the onset of DIHS, the patient was still undergoing immunotherapy including prednisolone.
Discussion
The period between oral administration of a causative drug and the onset of DIHS (1,2) for many cases is approximately 2 to 6 weeks. Unlike ordinary drug eruptions, DHIS does not occur immediately or within a few days following the oral administration of a drug. There have been reports of DIHS developing after long-term oral administration of a drug or within several weeks of discontinuation of therapy. Systematic symptoms of DIHS include fever, lymphadenopathy, rash (initially mottled papule or erythematous erythematosus, often transitioning to erythroderma), hepatic function disorder, renal function disorder, and hematologic abnormalities (leukocytosis, emergence of atypical lymphocytes, and eosinophil multiplication). Incidentally, characteristic erythematous findings such as erythema, edema of the face, red papule of the mouth, pustules, vesicles, and scales, are usually observed within 1 week of initial drug administration.
The causative drugs are limited. For this reason, DIHS was postulated to be due to an abnormality of metabolic enzymes (3, 4) . The most frequent causative agent of DIHS in Japan is carbamazepine. The symptoms of DHIS often progress even after stopping the administration of the causative drugs, and complete relief from symptoms often requires longer than 1 month. In typical cases, DIHS is clinically bimodal. This is due to reactivation of HHV-6. In other words, what has been regarded as a very specific course of drug eruption is a complex pathology of drug allergy and virus infection (3, 4) . Diagnostic criteria for DIHS have been proposed based on such clinical symptoms and the reactivation of HHV-6 ( Table 1) . Our patient met all seven criteria and was confirmed as a typical case of DIHS induced by salazosulphapyridine.
Reactivation of cytomegalovirus is frequently observed in DIHS (5, 6) ; cytomegalovirus is usually reactivated at the same time or later than HHV-6, suggesting that it could be related to clinical symptoms. Besides fever, mild liver dysfunction, and skin ulcer, severe symptoms such as myocarditis, pneumonia, and gastrointestinal bleeding may occur. If the symptoms of DIHS are prolonged, cytomegalovirus reactivation should be suspected (5, 6) . Cytomegalovirus infections in DIHS typically: 1) occur among elderly male patients, 2) develop 4 to 5 weeks following the onset of DIHS, 3) develop at the time of reactivation of HHV-6 and are related to HHV-6 DNA loads, and 4) are often prognostic (5) . Because cytomegalovirus infection can be treated with appropriate antiviral drugs (ganciclovir), it is important to consider cytomegalovirus reactivation when providing treatment for DIHS. The investigations for cytomegalovirus include IgG antibody titration, measurement of IgM antibody titer, antigenic test, virus DNA, and histopathological examination. Although these methods are the most reliable for the detection of viral DNA, the clinical antigenicity test is also useful (5) . The drug eruption in our patient was suspected to have been induced by dabigatran based on the clinical symptoms that appeared 4 days after its administration. While it is possible that there may have Table 1 
. The diagnostic criteria for drug-induced hypersensitivity syndrome (DIHS) based on such clinical symptoms and the reactivation of HHV-6
Diagnostic criteria 1 Maculopapular rash developing > 3 weeks after starting a limited number of drugs 2 Prolonged clinical symptoms 2 weeks after discontinuing the causative drug 3 Fever (> 38℃) 4 Elevation of liver enzyme (alanine aminotransferase [ALT] > 100 U/L) or involvement of other organs 5 Leukocytosis (> 11 × 10 3 /µL), atypical lymphocytosis (> 5%) or eosinophilia (> 1.5 × 10 3 /µL) 6 Lymphadenopathy 7 Human herpesvirus (HHV)-6 reactivation Diagnosis of typical DIHS requires the presence of all 7 criteria. Atypical DIHS is diagnosed in patients with 1-5. been cytomegalovirus reactivation, it may have been possible to avoid a severe cytomegalovirus infection such as central nervous system infection (7, 8) due to the increased dose of steroids. In addition, due to the early combination of insulin and steroid therapy, there was no transition to fulminant type I diabetic ketoacidosis (9) (10) (11) (12) . Although diagnosing DIHS was challenging, a severe course of DIHS was avoided by considering the possibility of reactivation of cytomegalovirus.
Hyponatremia was also observed in association with an exacerbation of IP. Due to the serum osmotic pressure, which was as low as 271 mOsm/kgH, and prompt improvement of the serum sodium level by fluid restriction, the SIADH was attributed to IP (13) . ADH is neuromodulated by two types of receptors, an osmotic receptor in the hypothalamus and a capacity receptor present in the left atrium, carotid artery, and aorta. Increased plasma osmotic pressure is detected by the osmotic receptor and a reduction in circulating blood volume or blood pressure is detected by the capacity receptor, which both in turn promote ADH secretion (13) . Sakuma et al. (14) described a patient with phenobarbital-induced hypersensitivity syndrome who had SIADH associated with limbic encephalitis during the course of the disease. However, to the best of our knowledge, there are no reports of DIHS combined with SIADH attributed to IP. In our case, the interstitial capillary blood vessels were impaired following IP in conjunction with reactivation of cytomegalovirus on the background of DIHS. ADH secretion may have been promoted via the capacity receptor due to reduction in the vascular bed in the lung and a decrease in venous return.
In general, steroids (prednisolone 30-50 mg/day) are effective for DIHS treatment, while in severe cases, high-dose steroids and steroid pulse therapy are used. Recently, high-dose intravenous gamma-globulin (IVIG) has been employed, and there are reports of combined use of IVIG with steroid therapy in severe cases (15) .
The administration of antiviral drugs is not necessary because HHV-6 reactivation usually occurs on a short-term basis. On the other hand, in the presence cytomegalovirus infection, with prolongation or severity of symptoms, it is necessary to consider administering ganciclovir (5) . In our patient, administration of steroid pulse therapy followed by a gradual decrease in dose prevented severe DIHS. This approach requires further investigation.
In conclusion, we encountered a case of DIHS induced by salazosulfapyridine combined with SIADH attributed to interstitial pneumonia 4 days following the administration of dabigatran that was difficult to diagnose. Timely diagnosis and an increase in the dose of steroids with subsequent tapering prevented worsening of DIHS. In the future, multidrug sensitization, potentially fatal infections, and convalescent autoimmune diseases may be combined (1, 2) , and careful follow-up is necessary.
